Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia ...

Real-World Analysis of the Adelphi Hemophilia Disease Specific Programme. Blood. 2024;144(Supplement 1):3973. 2. Malec L, Salehi H, Ball N, Lai S, Afonso M. Unmet Needs in People with Hemophilia ...

Research led by Christian Medical College in Vellore, India, has demonstrated the successful use of lentiviral vectors to ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...

India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...

Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access ...

Severe hemophilia A is managed with ... with a peripheral-blood vector copy number of 0.2 and 0.1 copies per cell, respectively, in the two group 1 participants, and 37.1 IU per deciliter (range ...

hemophilia, and other blood-related disorders. The demand for plasma-derived products in Vietnam is growing, driven by an increased awareness of plasma therapies, improvements in healthcare ...

Hemophilia A results from a deficiency in blood coagulation Factor VIII (FVIII ... Autologous hematopoietic stem cells (HSCs) were transduced with CD68-ET3-LV — a lentiviral vector including ...

The results of the study, "Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A" (Srivastava et al), were published by the New England Journal of Medicine, timed for release ...

In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...